TherapeuticsMD (NASDAQ:TXMD – Get Free Report) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
Institutional and Insider Ownership
30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
TherapeuticsMD has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.
Profitability
This table compares TherapeuticsMD and NRx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TherapeuticsMD | -6.64% | -1.09% | -0.78% |
| NRx Pharmaceuticals | -691.81% | N/A | -63.92% |
Earnings & Valuation
This table compares TherapeuticsMD and NRx Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TherapeuticsMD | $3.02 million | 6.93 | -$570,000.00 | $0.02 | 90.50 |
| NRx Pharmaceuticals | $3.39 million | 27.68 | -$28.62 million | ($0.55) | -3.95 |
TherapeuticsMD has higher earnings, but lower revenue than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for TherapeuticsMD and NRx Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
| NRx Pharmaceuticals | 2 | 0 | 6 | 0 | 2.50 |
NRx Pharmaceuticals has a consensus target price of $34.50, suggesting a potential upside of 1,489.86%. Given NRx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than TherapeuticsMD.
Summary
NRx Pharmaceuticals beats TherapeuticsMD on 8 of the 14 factors compared between the two stocks.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
